Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release into the blood stream a list of pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in … Read more
Rapid Dose Therapeutics Corp (RDTCF) - Net Assets
Latest net assets as of November 2025: $-6.65 Million USD
Based on the latest financial reports, Rapid Dose Therapeutics Corp (RDTCF) has net assets worth $-6.65 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.79 Million) and total liabilities ($10.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.65 Million |
| % of Total Assets | -175.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 424.13 |
Rapid Dose Therapeutics Corp - Net Assets Trend (2009–2025)
This chart illustrates how Rapid Dose Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rapid Dose Therapeutics Corp (2009–2025)
The table below shows the annual net assets of Rapid Dose Therapeutics Corp from 2009 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-02-28 | $-5.21 Million | -64.84% |
| 2024-02-29 | $-3.16 Million | -18.27% |
| 2023-02-28 | $-2.67 Million | -1161.41% |
| 2022-02-28 | $251.56K | +123.08% |
| 2021-02-28 | $-1.09 Million | -637.38% |
| 2020-02-29 | $-147.78K | -103.86% |
| 2019-02-28 | $3.83 Million | +30062.05% |
| 2018-02-28 | $-12.78K | +65.33% |
| 2017-02-28 | $-36.85K | -84.18% |
| 2015-02-28 | $-20.01K | +31.73% |
| 2014-02-28 | $-29.30K | -198.51% |
| 2013-02-28 | $-9.82K | -105.82% |
| 2012-02-29 | $168.73K | -28.64% |
| 2011-02-28 | $236.45K | +69.12% |
| 2010-02-28 | $139.82K | -4.64% |
| 2009-02-28 | $146.62K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rapid Dose Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4459322300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (February 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.26 Million | % |
| Other Comprehensive Income | $16.05K | % |
| Other Components | $11.12 Million | % |
| Total Equity | $-5.21 Million | 100.00% |
Rapid Dose Therapeutics Corp Competitors by Market Cap
The table below lists competitors of Rapid Dose Therapeutics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Investment Trust Of India Limited
NSE:THEINVEST
|
$10.60 Million |
|
Ieh Corp
PINK:IEHC
|
$10.60 Million |
|
Urbas Grupo Financiero SA
MC:UBS
|
$10.60 Million |
|
Woory Industrial Holdings Co.Ltd
KQ:072470
|
$10.60 Million |
|
Remsons Industries Limited
NSE:REMSONSIND
|
$10.60 Million |
|
Cloudastructure, Inc. Class A Common Stock
NASDAQ:CSAI
|
$10.59 Million |
|
Zeo ScientifiX, Inc.
OTCQB:ZEOX
|
$10.59 Million |
|
Galileo Mining Ltd
AU:GAL
|
$10.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rapid Dose Therapeutics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,157,954 to -5,205,529, a change of -2,047,575.
- Net loss of 5,404,265 reduced equity.
- New share issuances of 1,391,319 increased equity.
- Other factors increased equity by 1,965,371.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.40 Million | -103.82% |
| Share Issuances | $1.39 Million | +26.73% |
| Other Changes | $1.97 Million | +37.76% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Rapid Dose Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-02-28 | $0.49 | $0.18 | x |
| 2010-02-28 | $0.47 | $0.18 | x |
| 2011-02-28 | $0.49 | $0.18 | x |
| 2012-02-29 | $0.62 | $0.18 | x |
| 2013-02-28 | $-0.04 | $0.18 | x |
| 2014-02-28 | $-0.11 | $0.18 | x |
| 2015-02-28 | $-0.07 | $0.18 | x |
| 2016-02-29 | $-0.05 | $0.18 | x |
| 2017-02-28 | $-0.05 | $0.18 | x |
| 2018-02-28 | $0.00 | $0.18 | x |
| 2019-02-28 | $0.06 | $0.18 | x |
| 2020-02-29 | $0.00 | $0.18 | x |
| 2021-02-28 | $-0.01 | $0.18 | x |
| 2022-02-28 | $0.00 | $0.18 | x |
| 2023-02-28 | $-0.03 | $0.18 | x |
| 2024-02-29 | $-0.03 | $0.18 | x |
| 2025-02-28 | $-0.04 | $0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rapid Dose Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -259.18%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-220.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -2.30% | 0.00% | 0.00x | 1.03x | $-18.04K |
| 2010 | -4.87% | 0.00% | 0.00x | 1.17x | $-20.79K |
| 2011 | -33.82% | 0.00% | 0.00x | 1.05x | $-103.60K |
| 2012 | -40.13% | 0.00% | 0.00x | 1.32x | $-84.59K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-177.57K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.56K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.20K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.39K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-43.41K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-48.80K |
| 2019 | -297.78% | 0.00% | 0.00x | 1.51x | $-11.78 Million |
| 2020 | 0.00% | -7847.45% | 0.02x | 0.00x | $-7.95 Million |
| 2021 | 0.00% | -239.01% | 0.20x | 0.00x | $-1.70 Million |
| 2022 | -3373.73% | -484.42% | 0.57x | 12.20x | $-8.51 Million |
| 2023 | 0.00% | -530.42% | 0.32x | 0.00x | $-3.54 Million |
| 2024 | 0.00% | -422.16% | 0.54x | 0.00x | $-3.99 Million |
| 2025 | 0.00% | -259.18% | 1.28x | 0.00x | $-4.88 Million |
Industry Comparison
This section compares Rapid Dose Therapeutics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rapid Dose Therapeutics Corp (RDTCF) | $-6.65 Million | -2.30% | N/A | $10.60 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |